Loading...
Market
Outcome of PTC518 Phase 2 Trials by End of 2024?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Clinical trial results published by PTC Therapeutics or Novartis
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Safety established • 25%
Preliminary efficacy demonstrated • 25%
Both safety and efficacy demonstrated • 25%
No significant results • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%